Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 7/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17682301 | 0.91 | TRPA1 (0.55) | TRPA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL19601311 | 0.85 | TRPA1 (0.51) | TRPA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL17682167 | 0.85 | ADORA2B (0.58) | PDE4APDE4BPDE4CPDE4DADORA2B | |
| SCHEMBL17682317 | 0.84 | TRPA1 (0.52) | TRPA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL17682304 | 0.83 | KMT2A (0.54) | TRPA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL17682130 | 0.83 | TRPA1 (0.48) | TRPA1ADORA2BKMT2A | |
| SCHEMBL17682178 | 0.81 | SMN1; SMN2 (0.50) | TRPA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL17682319 | 0.81 | TRPA1 (0.36) | TRPA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL17682196 | 0.81 | KMT2A (0.46) | TRPA1PDE5APDE4APDE4BPDE4C | |
| SCHEMBL9350793 | 0.78 | ADORA2B (0.62) | PDE4APDE4BPDE4CPDE4DADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111233863-B | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-RE49128-E1 | Hydroxyl purine compounds and applications thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2022-07-12 | — | — | US | disclosed |
| US-RE49128-E1 | Hydroxyl purine compounds and applications thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2022-07-12 | — | — | US | disclosed |
| EP-3205652-B1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2022-03-09 | — | — | EP | disclosed |
| US-10098885-B2 | Hydroxyl purine compounds and applications thereof | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-10-16 | — | — | US | disclosed |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| EP-3205652-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | Medshine Discovery Inc. (CN) | 2017-08-16 | — | — | EP | disclosed |
| EP-3205652-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | Medshine Discovery Inc. (CN) | 2017-08-16 | — | — | EP | disclosed |
| WO-2017071606-A1 | MEDICAL USE OF HYDROXYL PURINE COMPOUND | 南京明德新药研发股份有限公司 | 2017-05-04 | — | — | WO | disclosed |
| WO-2016054971-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | 南京明德新药研发股份有限公司 | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | PNP, PDE2A, PDE7A | TRPA1 3239/4885PDE5A 11/4885PDE4A 9/4885 |
| US-10098885-B2 | Hydroxyl purine compounds and applications thereof | PNP, PDE2A, PDE7A | TRPA1 3239/4885PDE5A 11/4885PDE4A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.